Longbow Finance SA Acquires New Stake in Cencora, Inc. $COR

Longbow Finance SA bought a new position in Cencora, Inc. (NYSE:COR) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 33,767 shares of the company’s stock, valued at approximately $10,553,000.

A number of other institutional investors also recently modified their holdings of the company. Mirae Asset Global Investments Co. Ltd. raised its holdings in Cencora by 13.0% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 48,270 shares of the company’s stock worth $15,086,000 after acquiring an additional 5,543 shares in the last quarter. Acadian Asset Management LLC grew its stake in Cencora by 947.5% in the second quarter. Acadian Asset Management LLC now owns 257,082 shares of the company’s stock valued at $77,069,000 after purchasing an additional 232,539 shares in the last quarter. Mediolanum International Funds Ltd raised its stake in shares of Cencora by 133.0% during the 3rd quarter. Mediolanum International Funds Ltd now owns 56,293 shares of the company’s stock worth $17,342,000 after purchasing an additional 32,138 shares in the last quarter. Segment Wealth Management LLC bought a new stake in shares of Cencora during the 3rd quarter worth approximately $4,830,000. Finally, Synergy Asset Management LLC acquired a new stake in shares of Cencora in the 3rd quarter valued at approximately $10,093,000. 97.52% of the stock is currently owned by institutional investors.

Cencora Trading Down 3.8%

Shares of COR stock opened at $351.91 on Friday. Cencora, Inc. has a 12-month low of $237.71 and a 12-month high of $377.54. The company has a market capitalization of $68.27 billion, a PE ratio of 42.30, a price-to-earnings-growth ratio of 1.69 and a beta of 0.68. The firm has a 50 day moving average price of $347.08 and a two-hundred day moving average price of $327.83. The company has a quick ratio of 0.51, a current ratio of 0.92 and a debt-to-equity ratio of 3.62.

Cencora (NYSE:COR) last posted its earnings results on Wednesday, February 4th. The company reported $4.08 EPS for the quarter, beating the consensus estimate of $4.04 by $0.04. The company had revenue of $85.93 billion for the quarter, compared to the consensus estimate of $86.12 billion. Cencora had a return on equity of 176.54% and a net margin of 0.50%.The firm’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the business earned $3.73 earnings per share. As a group, analysts predict that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, March 2nd. Shareholders of record on Friday, February 13th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, February 13th. This represents a $2.40 annualized dividend and a yield of 0.7%. Cencora’s dividend payout ratio (DPR) is presently 28.85%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on COR shares. Mizuho boosted their target price on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. UBS Group lifted their price objective on shares of Cencora from $380.00 to $415.00 and gave the company a “buy” rating in a research report on Friday, November 7th. Barclays initiated coverage on shares of Cencora in a research note on Monday, December 8th. They set an “overweight” rating and a $400.00 price objective on the stock. JPMorgan Chase & Co. raised their target price on shares of Cencora from $417.00 to $419.00 and gave the company an “overweight” rating in a research note on Tuesday. Finally, Weiss Ratings raised Cencora from a “hold (c+)” rating to a “buy (b)” rating in a research report on Thursday, February 5th. One research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat.com, Cencora presently has an average rating of “Moderate Buy” and an average target price of $396.92.

Insider Transactions at Cencora

In other Cencora news, EVP Elizabeth S. Campbell sold 3,351 shares of Cencora stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $342.10, for a total value of $1,146,377.10. Following the completion of the sale, the executive vice president owned 23,891 shares in the company, valued at $8,173,111.10. The trade was a 12.30% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Robert P. Mauch sold 5,096 shares of the business’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $354.73, for a total transaction of $1,807,704.08. Following the completion of the sale, the chief executive officer directly owned 66,726 shares of the company’s stock, valued at $23,669,713.98. This represents a 7.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 20,316 shares of company stock valued at $7,151,265. 0.38% of the stock is currently owned by corporate insiders.

Cencora Profile

Cencora (NYSE:COR) is a global healthcare services and pharmaceutical distribution company that provides end-to-end solutions across the pharmaceutical supply chain. The company’s core activities include wholesale drug distribution, specialty drug distribution, and the operation of specialty pharmacies, complemented by logistics, cold-chain management and other fulfillment services designed to support complex and temperature-sensitive therapies.

Beyond physical distribution, Cencora offers a range of commercial and patient-focused services for pharmaceutical manufacturers and healthcare providers.